valrubicin valrubicin valrubicin (n-trifluoroacetyladriamycin-14-valerate, trade name valstar) is a chemotherapy drug used to treat bladder cancer. valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder. valrubicinclinical dataahfs/drugs.comconsumer drug informationmedlineplusa611021routes ofadministrationintravesicalatc codel01db09 (who) legal statuslegal status in general: ℞ (prescription only) pharmacokinetic databioavailabilitynegligibleprotein binding>99%metabolismnegligibleexcretionin urineidentifiers iupac name 2-oxo-2-hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate cas number56124-62-0 ypubchem cid454216drugbankdb00385 ychemspider399974 yunii2c6num6878chemblchembl1096885 ycomptox dashboard (epa)dtxsid9046497 echa infocard100.205.793 chemical and physical dataformulac34h36f3no13molar mass723.651 g·mol−13d model (jsmol)interactive image smiles fc(f)(f)c(=o)n5(o)(o(o4c3c(o)c2c(=o)c1c(oc)cccc1c(=o)c2c(o)c3c(o)(c(=o)coc(=o)cccc)c4)c5)c inchi inchi=1s/c34h36f3no13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47h,4-5,9-13h2,1-3h3,(h,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1 ykey:zockgbmqlcshfp-kqraqhldsa-n y (verify) it was originally launched as valstar in the u.s. in 1999 for intravesical therapy of bacille calmette-guérin (bcg)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues. valstar was relaunched on september 3, 2009. side effects blood in urine incontinence painful or difficult urination unusually frequent urination